Molecular and genetic aspects of cardiac fatty acid homeostasis in health and disease

European Heart Journal

Volumn 23, Issue 10, 2002, Pages 774-787

  De Windt, L J ^a   Cox, K ^b   Hofstra, L ^a   Doevendans, P A ^a,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; VERY LOW DENSITY LIPOPROTEIN;

ARRHYTHMOGENESIS; CARDIOMYOPATHY; ELECTRON TRANSPORT; ENERGY METABOLISM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY ACID TRANSPORT; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC DISORDER; HEART MUSCLE METABOLISM; HOMEOSTASIS; HUMAN; ISCHEMIC HEART DISEASE; MITOCHONDRIAL RESPIRATION; PRIORITY JOURNAL; RESPIRATORY CHAIN; REVIEW;

CARDIOMYOPATHIES; FATTY ACIDS; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; MOLECULAR BIOLOGY;

EID: 0036558547     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.2979     Document Type: Review

References (132)

1. Glatz JF, Luiken JJ, van Nieuwenhoven FA, van der Vusse GJ. Molecular mechanism of cellular uptake and intracellular translocation of fatty acids. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 3-9.
2. van der Vusse GJ, Glatz JF, Stam HC, Reneman RS. Fatty acid homeostasis in the normoxic and ischemic heart. Physiol Rev 1992; 72: 881-940.
3. Eaton S, Bartlett K, Pourfarzam M. Mammalian mitochondrial beta-oxidation. Biochem J 1996; 320: 345-57.
4. Grynberg A, Demaison L. Fatty acid oxidation in the heart. J Cardiovasc Pharmacol 1996; 28: S11-7.
5. Carnitine palmitoyltransferase deficiency. In: Gilman SGG, Waxman SG eds. Neurobase, 1st Edn. La Jolla: Arbor Publishing, 1995.
6. Chapoy PR, Angelini C, Brown WJ, Stiff JE, Shug AL, Cederbaum SD. Systemic carnitine deficiency - A treatable inherited lipid-storage disease presenting as Reye's syndrome. N Engl J Med 1980; 303: 1389-94.
7. Treem WR, Stanley CA, Finegold DN, Hale DE, Coates PM. Primary carnitine deficiency due to a failure of carnitine transport in kidney, muscle, and fibroblasts. N Engl J Med 1988; 319: 1331-6.
8. Stanley CA, Hale DE, Berry GT, Deleeuw S, Boxer J, Bonnefont JP. Brief report: A deficiency of carnitine-acylcarnitine translocase in the inner mitochondrial membrane. N Engl J Med 1992; 327: 19-23.
9. Rhead WJ, Amendt BA, Fritchman KS, Felts SJ. Dicarboxylic aciduria: Deficient [1-14C]octanoate oxidation and medium-chain acyl-CoA dehydrogenase in fibroblasts. Science 1983; 221: 73-5.
10. Yamaguchi S, Indo Y, Coates PM, Hashimoto T, Tanaka K. Identification of very-long-chain acyl-CoA dehydrogenase deficiency in three patients previously diagnosed with longchain acyl-CoA dehydrogenase deficiency. Pediatr Res 1993; 34: 111-3.
11. Izai K, Uchida Y, Orii T, Yamamoto S, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. I. Purification and properties of very-long-chain acylcoenzyme A dehydrogenase. J Biol Chem 1992; 267: 1027-33.
12. Aoyama T, Souri M, Ueno I et al. Cloning of human very-long-chain acyl-coenzyme A dehydrogenase and molecular characterization of its deficiency in two patients. Am J Hum Genet 1995; 57: 273-83.
13. Aoyama T, Souri M, Ushikubo S et al. Purification of human very-long-chain acyl-coenzyme A dehydrogenase and characterization of its deficiency in seven patients. J Clin Invest 1995; 95: 2465-73.
14. Hale DE, Batshaw ML, Coates PM et al. Long-chain acyl coenzyme A dehydrogenase deficiency: An inherited cause of nonketotic hypoglycemia. Pediatr Res 1985; 19: 666-71.
15. Uchida Y, Izai K, Orii T, Hashimoto T. Novel fatty acid beta-oxidation enzymes in rat liver mitochondria. II. Purification and properties of enoyl-coenzyme A (CoA) hydratase/3-hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase trifunctional protein. J Biol Chem 1992; 267: 1034-41.
16. Sims HF, Brackett JC, Powell CK et al. The molecular basis of pediatric long chain 3-hydroxyacyl-CoA dehydrogenase deficiency associated with maternal acute fatty liver of pregnancy. Proc Natl Acad Sci USA 1995; 92: 841-5.
17. Ijlst L, Ruiter JP, Vreijling J, Wanders RJ. Long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency: A new method to identify the G1528C mutation in genomic DNA showing its high frequency (approximately 90%) and identification of a new mutation (T2198C). J Inherit Metab Dis 1996; 19: 165-8.
18. Ushikubo S, Aoyama T, Kamijo T et al. Molecular characterization of mitochondrial trifunctional protein deficiency: Formation of the enzyme complex is important for stabilization of both alpha- and beta-subunits. Am J Hum Genet 1996; 58: 979-88.
19. Orii KE, Aoyama T, Souri M et al. Formation of the enzyme complex in mitochondria is required for function of trifunctional beta-oxidation protein. Biochem Biophys Res Commun 1996; 219: 773-7.
20. Loehr JP, Goodman SI, Frerman FE. Glutaric acidemia type II: Heterogeneity of clinical and biochemical phenotypes. Pediatr Res 1990; 27: 311-5.
21. Wilson GN, de Chadarevian JP, Kaplan P, Loehr JP, Frerman FE, Goodman SI. Glutaric aciduria type II: Review of the phenotype and report of an unusual glomerulopathy. Am J Med Genet 1989; 32: 395-401.
22. Kamiya M, Eimoto T, Kishimoto H et al. Glutaric aciduria type II: Autopsy study of a case with electron-transferring flavoprotein dehydrogenase deficiency. Pediatr Pathol 1990; 10: 1007-19.
23. Yamaguchi S, Orii T, Maeda K, Oshima M, Hashimoto T. A new variant of glutaric aciduria type 11: Deficiency of beta-subunit of electron transfer flavoprotein. J Inherit Metab Dis 1990; 13: 783-6.
24. Coates PM, Hale DE, Finocchiaro G, Tanaka K, Winter SC. Genetic deficiency of short-chain acyl-coenzyme A dehydrogenase in cultured fibroblasts from a patient with muscle carnitine deficiency and severe skeletal muscle weakness. J Clin Invest 1988; 81: 171-5.
25. Amendt BA, Greene C, Sweetman L et al. Short-chain acyl-coenzyme A dehydrogenase deficiency. Clinical and biochemical studies in two patients. J Clin Invest 1987; 79: 1303-9.
26. Wood PA, Amendt BA, Rhead WJ, Millington DS, Inoue F, Armstrong D. Short-chain acyl-coenzyme A dehydrogenase deficiency in mice. Pediatr Res 1989; 25: 38-43.
27. Guerra C, Koza RA, Walsh K, Kurtz DM, Wood PA, Kozak LP. Abnormal nonshivering thermogenesis in mice with inherited defects of fatty acid oxidation. J Clin Invest 1998; 102: 1724-31.
28. Kurtz DM, Tian L, Gower BA, Nagy TR, Pinkert CA, Wood PA. Transgenic studies of fatty acid oxidation gene expression in nonobese diabetic mice. J Lipid Res 2000; 41: 2063-70.
29. Kurtz DM, Rinaldo P, Rhead WJ et al. Targeted disruption of mouse long-chain acyl-CoA dehydrogenase gene reveals crucial roles for fatty acid oxidation. Proc Natl Acad Sci USA 1998; 95: 15592-7.
30. Doevendans PAvGW, Laarse A, van Bilsen M. Gene transcription in the cardiovascular system. Cardiologie 1997; 4: 221-9.
31. Doevendans PA. Implementation of molecular cardiology into clinical cardiology. Cardiologie 1999; 6: 210-7.
32. International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
33. Venter JC, Adams MD, Myers EW et al. The sequence of the human genome. Science 2001; 291: 1304-51.
34. Galderisi M, Anderson KM, Wilson PW, Levy D. Echocardiographic evidence for the existence of a distinct diabetic cardiomyopathy (the Framingham Heart Study). Am J Cardiol 1991; 68: 85-9.
35. Dubrey SW, Reaveley DR, Seed M et al. Risk factors for cardiovascular disease in IDDM. A study of identical twins. Diabetes 1994; 43: 831-5.
36. Friedman JJ. Vascular sensitivity and reactivity to norepinephrine in diabetes mellitus. Am J Physiol 1989; 256: H1134-8.
37. Kenno KA, Severson DL. Lipolysis in isolated myocardial cells from diabetic rat hearts. Am J Physiol 1985; 249: H1024-30.
38. Denton RM, Randle PJ. Concentrations of glycerides and phospholipids in rat heart and gastrocnemius muscles. Effects of alloxan-diabetes and perfusion. Biochem J 1967; 104: 416-22.
39. Eckel J, Reinauer H. Insulin action on glucose transport in isolated cardiac myocytes: Signalling pathways and diabetes-induced alterations. Biochem Soc Trans 1990; 18: 1125-7.
40. Garvey WT, Hardin D, Juhaszova M, Dominguez JH. Effects of diabetes on myocardial glucose transport system in rats: Implications for diabetic cardiomyopathy. Am J Physiol 1993; 264: H837-44.
41. Chen V, Ianuzzo CD. Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 1982; 60: 1251-6.
42. Lopashuk GD. Fatty acid metabolism in the heart following diabetes. In: Chatham JCPD, Forder JR, McNeill JH, eds. The Heart in Diabetes. Boston: Kluwer Academic Publishers, 1996: 215-51.
43. Adams RJ, Cohen DW, Gupte S et al. In vitro effects of palmitylcarnitine on cardiac plasma membrane Na,K-ATPase, and sarcoplasmic reticulum Ca2+-ATPase and Ca2+ transport. J Biol Chem 1979; 254: 12404-10.
44. Kramer JH, Weglicki WB. Inhibition of sarcolemmal Na+- K+-ATPase by palmitoyl carnitine: Potentiation by propranolol. Am J Physiol 1985; 248: H75-81.
45. Ashavaid TF, Colvin RA, Messineo FC, MacAlister T, Katz AM. Effects of fatty acids on Na/Ca exchange in cardiac sarcolemmal membranes. J Mol Cell Cardiol 1985; 17: 851-61.
46. Dhalla NS, Kolar F, Shah KR, Ferrari R. Effects of some L-carnitine derivatives on heart membrane ATPases. Cardiovasc Drugs Ther 1991; 5 (Suppl 1): 25-30.
47. 2+ in toxic cell killing. Trends Pharmacol Sci 1989; 10: 281-5.
48. Corr PB, Gross RW, Sobel BE. Amphipathic metabolites and membrane dysfunction in ischemic myocardium. Circ Res 1984; 55: 135-54.
49. Nicholl TA, Lopaschuk GD, McNeill JH. Effects of free fatty acids and dichloroacetate on isolated working diabetic rat heart. Am J Physiol 1991; 261: H1053-9.
50. Rodrigues B, Grassby PF, Battell ML, Lee SY, McNeill JH. Hypertriglyceridemia in experimental diabetes: Relationship to cardiac dysfunction. Can J Physiol Pharmacol 1994; 72: 447-55.
51. Rosen P, Reinauer H. Inhibition of carnitine palmitoyltransferase 1 by phenylalkyloxiranecarboxylic acid and its influence on lipolysis and glucose metabolism in isolated, perfused hearts of streptozotocin-diabetic rats. Metabolism 1984; 33: 177-85.
52. Jennings RB, Ganote CE, Reimer KA. Ischemic tissue injury. Am J Pathol 1975; 81: 179-98.
53. Ganote CE, Seabra-Gomes R, Nayler WG, Jennings RB. Irreversible myocardial injury in anoxic perfused rat hearts. Am J Pathol 1975; 80: 419-50.
54. van der Vusse GJ, Roemen TH, Prinzen FW, Coumans WA, Reneman RS. Uptake and tissue content of fatty acids in dog myocardium under normoxic and ischemic conditions. Circ Res 1982; 50: 538-46.
55. Li QA, Altschuld RA, Stokes BT. Myocyte deenergization and intracellular free calcium dynamics. Am J Physiol 1988; 255: C162-8.
56. 2+ in hypoxic cardiomyocytes. In: Piper HMIG, ed. Isolated Adult Cardiomyocytes. Boca Raton, FL: CRC Press, 1989: 287-308.
57. Miyamae M, Camacho SA, Weiner MW, Figueredo VM. Attenuation of postischemic reperfusion injury is related to prevention of [Ca2+]m overload in rat hearts. Am J Physiol 1996; 271: H2145-53.
58. Leperre A, Millart H, Prevost A, Trenque T, Kantelip JP, Keppler BK. Compared effects of ruthenium red and cis [Ru(NH3)4CI2] Cl on the isolated ischaemic-reperfused rat heart. Fundam Clin Pharmacol 1995; 9: 545-53.
59. Tan ZT. Ruthenium red, ribose, and adenine enhance recovery of reperfused rat heart. Coron Artery Dis 1993; 4: 305-9.
60. 2+ in myocytes and perfused hearts: The role of mitochondria. J Mol Cell Cardiol 1989; 21: 963-73.
61. Grover GJ, Dzwonczyk S, Sleph PG. Ruthenium red improves postischemic contractile function in isolated rat hearts. J Cardiovasc Pharmacol 1990; 16: 783-9.
62. Figueredo VM, Dresdner KP, Jr, Wolney AC, Keller AM. Postischaemic reperfusion injury in the isolated rat heart: Effect of ruthenium red. Cardiovasc Res 1991; 25: 337-42.
63. Goodwin GW, Taegtmeyer H. Metabolic recovery of isolated working rat heart after brief global ischemia. Am J Physiol 1994; 267: H462-70.
64. Taegtmeyer H, Roberts AF, Raine AE. Energy metabolism in reperfused heart muscle: Metabolic correlates to return of function. J Am Coll Cardiol 1985; 6: 864-70.
65. Lopaschuk GD, Collins-Nakai R, Olley PM et al. Plasma fatty acid levels in infants and adults after myocardial ischemia. Am Heart J 1994; 128: 61-7.
66. Chen ZP, McConell GK, Michell BJ, Snow RJ, Canny BJ, Kemp BE. AMPK signaling in contracting human skeletal muscle: Acetyl-CoA carboxylase and NO synthase phosphorylation. Am J Physiol Endocrinol Metab 2000; 279: E1202-6.
67. Dagher Z, Ruderman N, Tornheim K, Ido Y. The effect of AMP-activated protein kinase and its activator AICAR on the metabolism of human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999; 265: 112-5.
68. Kudo N, Gillespie JG, Kung L et al. Characterization of 5′AMP-activated protein kinase activity in the heart and its role in inhibiting acetyl-CoA carboxylase during reperfusion following ischemia. Biochim Biophys Acta 1996; 1301: 67-75.
69. Liu B, Clanachan AS, Schulz R, Lopaschuk GD. Cardiac efficiency is improved after ischemia by altering both the source and fate of protons. Circ Res 1996; 79: 940-8.
70. 2 during reperfusion of ischemic hearts. Am J Physiol 1996; 270: H72-80.
71. Dobsak P, Courderot-Masuyer C, Zeller M et al. Antioxidative properties of pyruvate and protection of the ischemic rat heart during cardioplegia. J Cardiovasc Pharmacol 1999; 34: 651-9.
72. Liu Q, Clanachan AS, Lopaschuk GD. Acute effects of triiodothyronine on glucose and fatty acid metabolism during reperfusion of ischemic rat hearts. Am J Physiol 1998; 275: E392-9.
73. Lopaschuk GD, Saddik M. The relative contribution of glucose and fatty acids to ATP production in hearts reperfused following ischemia. Mol Cell Biochem 1992; 116: 111-6.
74. McVeigh JJ, Lopaschuk GD. Dichloroacetate stimulation of glucose oxidation improves recovery of ischemic rat hearts. Am J Physiol 1990; 259: H1079-85.
75. Mochizuki S, Neely JR. Energy metabolism during reperfusion following ischemia. J Physiol 1980; 76: 805-12.
76. Lopaschuk G. Regulation of carbohydrate metabolism in ischemia and reperfusion. Am Heart J 2000; 139: S115-9.
77. Lopaschuk GD, McNeil GF, McVeigh JJ. Glucose oxidation is stimulated in reperfused ischemic hearts with the carnitine palmitoyltransferase 1 inhibitor. Etomoxir. Mol Cell Biochem 1989; 88: 175-9.
78. Liu Y, Rosenthal RE, Starke-Reed P, Fiskum G. Inhibition of postcardiac arrest brain protein oxidation by acetyl-L-carnitine. Free Radic Biol Med 1993; 15: 667-70.
79. Madden MC, Wolkowicz PE, Pohost GM, McMillin JB, Pike MM. Acylcarnitine accumulation does not correlate with reperfusion recovery in palmitate-perfused rat hearts. Am J Physiol 1995; 268: H2505-12.
80. Coleman GM, Gradinac S, Taegtmeyer H, Sweeney M, Frazier OH. Efficacy of metabolic support with glucose-insulin-potassium for left ventricular pump failure after aortocoronary bypass surgery. Circulation 1989; 80: 191-6.
81. Gradinac S, Coleman GM, Taegtmeyer H, Sweeney MS, Frazier OH. Improved cardiac function with glucose-insulin-potassium after aortocoronary bypass grafting. Ann Thorac Surg 1989; 48: 484-9.
82. Ceremuzynski L, Budaj A, Czepiel A et al. Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: Results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999; 13: 191-200.
83. De Windt LJ, Reneman RS, van der Vusse GJ, van Bilsen M. Phospholipase A2-mediated hydrolysis of cardiac phospholipids: The use of molecular and transgenic techniques. Mol Cell Biochem 1998; 180: 65-73.
84. Post JA, Langer GA, Op den Kamp JA, Verkleij AJ. Phospholipid asymmetry in cardiac sarcolemma. Analysis of intact cells and 'gas-dissected' membranes. Biochim Biophys Acta 1988; 943: 256-66.
85. van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS. Lipid alterations in isolated, working rat hearts during ischemia and reperfusion: Its relation to myocardial damage. Circ Res 1989; 64: 304-14.
86. Chien KR, Han A, Sen A, Buja LM, Willerson JT. Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids. Circ Res 1984; 54: 313-22.
87. van Bilsen M, van der Vusse GJ. Phospholipase-A2-dependent signalling in the heart. Cardiovasc Res 1995; 30: 518-29.
88. van Bilsen M, van der Vusse GJ, Willemsen PH, Coumans WA, Roemen TH, Reneman RS. Effects of nicotinic acid and mepacrine on fatty acid accumulation and myocardial damage during ischemia and reperfusion. J Mol Cell Cardiol 1990; 22: 155-63.
89. Jans SW, Willems J, van Bilsen M, Reutelingsperger CP, van der Vusse GJ. Phospholipid degradation in energy-deprived cardiac myocytes: Does annexin V play a role? J Mol Cell Cardiol 1997; 29: 1401-10.
90. van der Vusse GJ, van Bilsen M, Reneman RS. Ischemia and reperfusion induced alterations in membrane phospholipids: An overview. Ann NY Acad Sci 1994; 723: 1-14.
91. Jones RL, Miller JC, Hagler HK, Chien KR, Willerson JT, Buja LM. Association between inhibition of arachidonic acid release and prevention of calcium loading during ATP depletion in cultured rat cardiac myocytes. Am J Pathol 1989; 135: 541-56.
92. Chien KR, Sen A, Reynolds R et al. Release of arachidonate from membrane phospholipids in cultured neonatal rat myocardial cells during adenosine triphosphate depletion. Correlation with the progression of cell injury. J Clin Invest 1985; 75: 1770-80.
93. Gunn MD, Sen A, Chang A, Willerson JT, Buja LM, Chien KR. Mechanisms of accumulation of arachidonic acid in cultured myocardial cells during ATP depletion. Am J Physiol 1985; 249: H1188-94.
94. Sen A, Buja LM, Willerson JT, Chien KR. Membrane phospholipid metabolism during myocardial ischaemia: Past, present and future. Basic Res Cardiol 1987; 82: 121-5.
95. De Windt LJ, Willems J, Coumans WA et al. The ischemic-reperfused isolated working mouse heart: Membrane damage and type IIA secretory phospholipase A2. Am J Physiol 2001; 280: H2572-H2580.
96. Bevers EM, Comfurius P, Dekkers DW, Zwaal RF. Lipid translocation across the plasma membrane of mammalian cells. Biochim Biophys Acta 1999; 1439: 317-30.
97. Martin SJ, Reutelingsperger CP, McGahon AJ et al. Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of Bcl-2 and Abl. J Exp Med 1995; 182: 1545-56.
98. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 1997; 89: 1121-32.
99. Bratton DL, Fadok VA, Richter DA, Kailey JM, Guthrie LA, Henson PM. Appearance of phosphatidylserine on apoptotic cells requires calcium-mediated nonspecific flip-flop and is enhanced by loss of the aminophospholipid translocase. J Biol Chem 1997; 272: 26159-65.
100. van Engeland M, Kuijpers HJ, Ramaekers FC, Reutelingsperger CP, Schutte B. Plasma membrane alterations and cytoskeletal changes in apoptosis. Exp Cell Res 1997; 235: 421-30.
101. Reutelingsperger CP, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci 1997; 53: 527-32.
102. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, Pals ST, van Oers MH. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 1994; 84: 1415-20.
103. Dumont EA, Hofstra L, van Heerde WL et al. Cardiomyocyte death induced by myocardial ischemia and reperfusion: Measurement with recombinant human annexin-V in a mouse model. Circulation 2000; 102: 1564-8.
104. Hofstra L, Liem IH, Dumont EA et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356: 209-12.
105. Corr PB, Cain ME, Witkowski FX, Price DA, Sobel BE. Potential arrhythmogenic electrophysiological derangements in canine Purkinje fibers induced by lysophosphoglycerides. Circ Res 1979; 44: 822-32.
106. DaTorre SD, Creer MH, Pogwizd SM, Corr PB. Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart. J Mol Cell Cardiol 1991; 23 (Suppl 1): 11-22.
107. Man RY, Kinnaird AA, Bihler I, Choy PC. The association of lysophosphatidylcholine with isolated cardiac myocytes. Lipids 1990; 25: 450-4.
108. 2+ accumulation in rat cardiac myocytes. Am J Physiol 1983; 244: H32-8.
109. Woodley SL, Ikenouchi H, Barry WH. Lysophosphatidylcholine increases cytosolic calcium in ventricular myocytes by direct action on the sarcolemma. J Mol Cell Cardiol 1991; 23: 671-80.
110. Pitts BJ, Okhuysen CH. Effects of palmitoyl carnitine and LPC on cardiac sarcolemmal Na+-K+-ATPase. Am J Physiol 1984; 247: H840-6.
111. Undrovinas AI, Fleidervish IA, Makielski JC. Inward sodium current at resting potentials in single cardiac myocytes induced by the ischemic metabolite lysophosphatidylcholine. Circ Res 1992; 71: 1231-41.
112. Magishi K, Kimura J, Kubo Y, Abiko Y. Exogenous lysophosphatidylcholine increases non-selective cation current in guinea-pig ventricular myocytes. Pflugers Arch 1996; 432: 345-50.
113. Xiao YF, Kang JX, Morgan JP, Leaf A. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1995; 92: 11000-4.
114. Xiao YF, Gomez AM, Morgan JP, Lederer WJ, Leaf A. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci USA 1997; 94: 4182-7.
115. Xiao YF, Wright SN, Wang GK, Morgan JP, Leaf A. Fatty acids suppress voltage-gated Na+ currents in HEK293t cells transfected with the alpha-subunit of the human cardiac Na+ channel. Proc Natl Acad Sci USA 1998; 95: 2680-5.
116. Kang JX, Leaf A. Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 2000; 71: 202S-7S.
117. Burr ML, Fehily AM, Gilbert JF et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART). Lancet 1989; 2: 757-61.
118. de Lorgeril M, Renaud S, Mamelle N et al. Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease. Lancet 1994; 343: 1454-9.
119. Siscovick DS, Raghunathan TE, King I et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-7.
120. Singh RB, Niaz MA, Sharma JP, Kumar R, Rastogi V, Moshiri M. Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: The Indian experiment of infarct survival - 4. Cardiovasc Drugs Ther 1997; 11: 485-91.
121. Christensen JH, Korup E, Aaroe J et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am J Cardiol 1997; 79: 1670-3.
122. Albert CM, Hennekens CH, O'Donnell CJ et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-8.
123. Power GWNE. Dietary fatty acids influence the activity and metabolic control of mitochondrial carnitine palmitoyltransferase I in rat heart and skeletal muscle. J Nutr 1997; 127: 2142-50.
124. van Bilsen M, de Vries JE, van der Vusse GJ. Long-term effects of fatty acids on cell viability and gene expression of neonatal cardiac myocytes. Prostaglandins Leukot Essent Fatty Acids 1997; 57: 39-45.
125. van der Lee KA, Vork MM, De Vries JE et al. Long-chain fatty acid-induced changes in gene expression in neonatal cardiac myocytes. J Lipid Res 2000; 41: 41-7.
126. Osumi T, Wen JK, Hashimoto T. Two cis-acting regulatory sequences in the peroxisome proliferator-responsive enhancer region of rat acyl-CoA oxidase gene. Biochem Biophys Res Commun 1991; 175: 866-71.
127. Tugwood JD, Issemann I, Anderson RG, Bundell KR, McPheat WL, Green S. The mouse peroxisome proliferator activated receptor recognizes a response element in the 5+ flanking sequence of the rat acyl CoA oxidase gene. EMBO J 1992; 11: 433-9.
128. Zhang B, Marcus SL, Sajjadi FG et al. Identification of a peroxisome proliferator-responsive element upstream of the gene encoding rat peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase. Proc Natl Acad Sci USA 1992; 89: 7541-5.
129. Gearing KL, Gottlicher M, Teboul M, Widmark E, Gustafsson JA. Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor. Proc Natl Acad Sci USA 1993; 90: 1440-4.
130. Kliewer SA, Umesono K, Noonan DJ, Heyman RA, Evans RM. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771-4.
131. Fruchart JC, Duriez P, Staels B. Peroxisome proliferator-activated receptor-alpha activators regulate genes governing lipoprotein metabolism, vascular inflammation and atherosclerosis. Curr Opin Lipidol 1999; 10: 245-57.
132. Bishop-Bailey D. Peroxisome proliferator-activated receptors in the cardiovascular system. Br J Pharmacol 2000; 129: 823-34.